Category: Phenotype

LitAlert ~~ GeneLit.com

    • Triple-negative breast cancer therapy: Current and future perspectives (Review).
    • Won KA, Spruck C.
    • Int J Oncol. 2020 Dec;57(6):1245-1261. doi: 10.3892/ijo.2020.5135. Epub 2020 Oct 16.

    • Evidence for familial clustering in breast cancer age of onset.
    • Von Holle A, O'Brien KM, Sandler DP, Weinberg CR.
    • Int J Epidemiol. 2020 Nov 28:dyaa201. doi: 10.1093/ije/dyaa201. Epub ahead of print.

    • New Perspectives for Resistance to PARP Inhibitors in Triple-Negative Breast Cancer.
    • Han Y, Yu X, Li S, Tian Y, Liu C.
    • Front Oncol. 2020 Nov 25;10:578095. doi: 10.3389/fonc.2020.578095.

    • Insights into the impacts of BRCA mutations on clinicopathology and management of early-onset triple-negative breast cancer.
    • Ye F, He M, Huang L, Lang G, Hu X, Shao Z, Di G, Cao A.
    • Front Oncol. 2020 Nov 24;10:574813. doi: 10.3389/fonc.2020.574813.

    • SYNCHRONOUS AND METACHRONUS BREAST AND OVARIAN CANCER: EXPERIENCE FROM TWO LARGE CANCER CENTER.
    • Tasca G, Dieci MV, Baretta Z, Faggioni G, Montagna M, Nicoletto MO, Peccatori FA, Guarneri V, Colombo N.
    • Front Oncol. 2020 Nov 16;10:608783. doi: 10.3389/fonc.2020.608783.

    • Update Breast Cancer 2020 Part 4 - Advanced Breast Cancer.
    • Tesch H, Müller V, Wöckel A, Ettl J, Belleville E, Schütz F, Hartkopf A, Thill M, Huober J, Fasching PA, Kolberg HC, Schulmeyer CE, Welslau M, Overkamp F, Fehm TN, Lux MP, Schneeweiss A, Lüftner D, Janni W.
    • Geburtshilfe Frauenheilkd. 2020 Nov;80(11):1115-1122. doi: 10.1055/a-1270-7481. Epub 2020 Nov 6.

    • LitAlert ~~ GeneLit.com

    • Pathogenic Germline Mutations of DNA Repair Pathway Components in Early-Onset Sporadic Colorectal Polyp and Cancer Patients.
    • Chang PY, Chang SC, Wang MC, Chen JS, Tsai WS, You JF, Chen CC, Liu HL, Chiang JM.
    • Cancers (Basel). 2020 Nov 28;12(12):E3560. doi: 10.3390/cancers12123560.

    • TP53 germline mutations in the context of families with hereditary breast and ovarian cancer: a clinical challenge.
    • Grill S, Ramser J, Hellebrand H, Pfarr N, Boxberg M, Brambs C, Ditsch N, Meindl A, Groß E, Meitinger T, Kiechle M, Quante AS.
    • Arch Gynecol Obstet. 2020 Nov 27. doi: 10.1007/s00404-020-05883-x. Epub ahead of print.

    • LitAlert ~~ GeneLit.com

    • Olaparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer and a BRCA1 and/or BRCA2 mutation: SOLO1 China cohort.
    • Wu L, Zhu J, Yin R, Wu X, Lou G, Wang J, Gao Y, Kong B, Lu X, Zhou Q, Wang Y, Chen Y, Lu W, Li W, Cheng Y, Liu J, Ma X, Zhang J.
    • Gynecol Oncol. 2020 Nov 26:S0090-8258(20)34013-0. doi: 10.1016/j.ygyno.2020.10.005. Epub ahead of print.

    • Olaparib Monotherapy as Primary Treatment in Unselected Triple Negative Breast Cancer.
    • Eikesdal HP, Yndestad S, Elzawahry A, Llop-Guevara A, Gilje B, Blix ES, Espelid H, Lundgren S, Geisler J, Vagstad G, Venizelos A, Minsaas L, Leirvaag B, Gudlaugsson EG, Vintermyr OK, Aase HS, Aas T, Balmaña J, Serra V, Janssen EAM, Knappskog S, Lønning PE.
    • Ann Oncol. 2020 Nov 23:S0923-7534(20)43164-3. doi: 10.1016/j.annonc.2020.11.009. Epub ahead of print.

    • Lived experiences of women reporting fatigue during PARP inhibitor maintenance treatment for advanced ovarian cancer: A qualitative study.
    • Poort H, Fenton ATHR, Thompson E, Dinardo MM, Liu JF, Arch JJ, Wright AA.
    • Gynecol Oncol. 2020 Nov 12:S0090-8258(20)34056-7. doi: 10.1016/j.ygyno.2020.10.034. Epub ahead of print.

    • LitAlert ~~ GeneLit.com

    • Tumor phenotype and concordance in synchronous bilateral breast cancer in young women.
    • Pak LM, Gaither R, Rosenberg SM, Ruddy KJ, Tamimi RM, Peppercorn J, Schapira L, Borges VF, Come SE, Warner E, Snow C, Collins LC, King TA, Partridge AH.
    • Breast Cancer Res Treat. 2020 Nov 26. doi: 10.1007/s10549-020-06027-0. Epub ahead of print.

    • Olaparib is effective for recurrent urothelial carcinoma with BRCA2 pathogenic germline mutation: first report on olaparib response in recurrent UC.
    • Yang H, Liu Z, Wang Y, Li J, Li R, Wang Q, Hu C, Jiang H, Wu H, Song L, Bai Y.
    • Ther Adv Med Oncol. 2020 Nov 11;12:1758835920970845. doi: 10.1177/1758835920970845.

    • Identification of Novel BRCA1 and RAD50 Mutations Associated With Breast Cancer Predisposition in Tunisian Patients.
    • Mighri N, Hamdi Y, Boujemaa M, Othman H, Ben Nasr S, El Benna H, Mejri N, Labidi S, Ayari J, Jaidene O, Bouaziz H, Ben Rekaya M, M'rad R, Haddaoui A, Rahal K, Boussen H, Boubaker S, Abdelhak S.
    • Front Genet. 2020 Nov 6;11:552971. doi: 10.3389/fgene.2020.552971.

    • Sentinel lymph node biopsy should be considered for clinically node-negative breast cancer regardless of BRCA1/2 mutation status.
    • Huang X, Liu JQ, Zhou YD, Xu Y, Chen C, Wang X, Cao X, Yao R, Sun Q.
    • Ann Transl Med. 2020 Sep;8(18):1183. doi: 10.21037/atm-20-5996.

    • Morphological and molecular heterogeneity of epithelial ovarian cancer: Therapeutic implications.
    • Romero I, Leskelä S, Mies BP, Velasco AP, Palacios J.
    • EJC Suppl. 2020 Aug 22;15:1-15. doi: 10.1016/j.ejcsup.2020.02.001.

    • LitAlert ~~ GeneLit.com

    • Alternative genomic diagnoses for individuals with a clinical diagnosis of Dubowitz syndrome.
    • Dyment DA, O'Donnell-Luria A, Agrawal PB, Coban Akdemir Z, Aleck KA, Antaki D, Al Sharhan H, Au PB, Aydin H, Beggs AH, Bilguvar K, Boerwinkle E, Brand H, Brownstein CA, Buyske S, Chodirker B, Choi J, Chudley AE, Clericuzio CL, Cox GF, Curry C, de Boer E, de Vries BBA, Dunn K, Dutmer CM, England EM, Fahrner JA, Geckinli BB, Genetti CA, Gezdirici A, Gibson WT, Gleeson JG, Greenberg CR, Hall A, Hamosh A, Hartley T, Jhangiani SN, Karaca E, Kernohan K, Lauzon JL, Lewis MES, Lowry RB, López-Giráldez F, Matise TC, McEvoy-Venneri J, McInnes B, Mhanni A, Garcia Minaur S, Moilanen J, Nguyen A, Nowaczyk MJM, Posey JE, Õunap K, Pehlivan D, Pajusalu S, Penney LS, Poterba T, Prontera P, Doriqui MJR, Sawyer SL, Sobreira N, Stanley V, Torun D, Wargowski D, Witmer PD, Wong I, Xing J, Zaki MS, Zhang Y; Care4Rare Consortium; Centers for Mendelian Genomics, Boycott KM, Bamshad MJ, Nickerson DA, Blue EE, Innes AM.
    • Am J Med Genet A. 2020 Oct 24. doi: 10.1002/ajmg.a.61926. Epub ahead of print.

    • Impact of Personalized Genetic Breast Cancer Risk Estimation With Polygenic Risk Scores on Preventive Endocrine Therapy Intention and Uptake.
    • Kim JO, Schaid DJ, Vachon CM, Cooke A, Couch FJ, Kim CA, Sinnwell JP, Hasadsri L, Stan DL, Goldenberg BA, Neal L, Grenier D, Degnim AC, Thicke LA, Pruthi S.
    • Cancer Prev Res (Phila). 2020 Oct 23:canprevres.0154.2020. doi: 10.1158/1940-6207.CAPR-20-0154. Epub ahead of print.

    • Inflammatory indexes as predictive factors for platinum sensitivity and as prognostic factors in recurrent epithelial ovarian cancer patients: a MITO24 retrospective study.
    • Farolfi A, Scarpi E, Greco F, Bergamini A, Longo L, Pignata S, Casanova C, Cormio G, Bologna A, Orditura M, Zavallone L, Attademo L, Gallà V, Franzese E, Pigozzi E, Loizzi V, Giorda G, Giardina D, Cioffi R, De Giorgi U.
    • Sci Rep. 2020 Oct 23;10(1):18190. doi: 10.1038/s41598-020-75316-x.

    • Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study).
    • Fasching PA, Link T, Hauke J, Seither F, Jackisch C, Klare P, Schmatloch S, Hanusch C, Huober J, Stefek A, Seiler S, Schmitt WD, Uleer C, Doering G, Rhiem K, Schneeweiss A, Engels K, Denkert C, Schmutzler RK, Hahnen E, Untch M, Burchardi N, Blohmer JU, Loibl S; GBG and AGO-B.
    • Ann Oncol. 2020 Oct 21:S0923-7534(20)42963-1. doi: 10.1016/j.annonc.2020.10.471. Epub ahead of print.

    • Assessment of structural chromosomal instability phenotypes as biomarkers of carboplatin response in Triple Negative Breast Cancer: the TNT trial.
    • Sipos O, Tovey H, Quist J, Haider S, Nowinski S, Gazinska P, Kernaghan S, Toms C, Maguire S, Orr N, Linn SC, Owen J, Gillett C, Pinder SE, Bliss JM, Tutt A, Cheang MCU, Grigoriadis A.
    • Ann Oncol. 2020 Oct 21:S0923-7534(20)42977-1. doi: 10.1016/j.annonc.2020.10.475. Epub ahead of print.

    • LitAlert ~~ GeneLit.com

    • An evaluation of olaparib for the treatment of pancreatic cancer.
    • Vaishampayan UN.
    • Expert Opin Pharmacother. 2020 Oct 23. doi: 10.1080/14656566.2020.1837113. Epub ahead of print.
    • Review

    • Cytologic studies of in vivo fallopian tube specimens in patients undergoing salpingo-oophorectomy.
    • Pramanik S, Yang E, Wu W.
    • Cytojournal. 2020 Aug 10;17:19. doi: 10.25259/CytoJournal_7_2020.

    • LitAlert ~~ GeneLit.com

    • Circulating growth factor concentrations and breast cancer risk: a nested case-control study of IGF-1, IGFBP-3, and breast cancer in a family-based cohort.
    • Monson KR, Goldberg M, Wu HC, Santella RM, Chung WK, Terry MB.
    • Breast Cancer Res. 2020 Oct 22;22(1):109. doi: 10.1186/s13058-020-01352-0.

    • Cell type-specific genotoxicity in estrogen-exposed ovarian and fallopian epithelium.
    • Song L, Tang Z, Peng C, Yang Y, Guo C, Wang D, Guo L, Chen J, Liu C.
    • BMC Cancer. 2020 Oct 21;20(1):1020. doi: 10.1186/s12885-020-07524-7.

    • Exome sequencing and characterization of 49,960 individuals in the UK Biobank.
    • Van Hout CV, Tachmazidou I, Backman JD, Hoffman JD, Liu D, Pandey AK, Gonzaga-Jauregui C, Khalid S, Ye B, Banerjee N, Li AH, O'Dushlaine C, Marcketta A, Staples J, Schurmann C, Hawes A, Maxwell E, Barnard L, Lopez A, Penn J, Habegger L, Blumenfeld AL, Bai X, O'Keeffe S, Yadav A, Praveen K, Jones M, Salerno WJ, Chung WK, Surakka I, Willer CJ, Hveem K, Leader JB, Carey DJ, Ledbetter DH; Geisinger-Regeneron DiscovEHR Collaboration, Cardon L, Yancopoulos GD, Economides A, Coppola G, Shuldiner AR, Balasubramanian S, Cantor M; Regeneron Genetics Center, Nelson MR, Whittaker J, Reid JG, Marchini J, Overton JD, Scott RA, Abecasis GR, Yerges-Armstrong L, Baras A.
    • Nature. 2020 Oct 21. doi: 10.1038/s41586-020-2853-0. Epub ahead of print.

    • Lessons learned from setting up a prospective, longitudinal, multicenter study with women at high risk for breast cancer.
    • Patuleia SIS, Hagenaars SC, Moelans CB, Ausems MGEM, van Gils CH, Tollenaar RAEM, Van Diest PJ, Mesker WE, van der Wall E.
    • Cancer Epidemiol Biomarkers Prev. 2020 Oct 20:cebp.0770.2020. doi: 10.1158/1055-9965.EPI-20-0770. Epub ahead of print.
    • Review

    • PARP Inhibitors in Cancer Diagnosis and Therapy.
    • Chan CY, Tan KV, Cornelissen B.
    • Clin Cancer Res. 2020 Oct 20:clincanres.2766.2020. doi: 10.1158/1078-0432.CCR-20-2766. Epub ahead of print.
    • Review

    • Tumor site discordance in mismatch repair deficiency in synchronous endometrial and ovarian cancers.
    • Kim SR, Tone A, Kim R, Cesari M, Clarke B, Eiriksson L, Hart T, Aronson M, Holter S, Lytwyn A, Maganti M, Oldfield L, Gallinger S, Bernardini MQ, Oza AM, Djordjevic B, Lerner-Ellis J, Van de Laar E, Vicus D, Pugh TJ, Pollett A, Ferguson SE.
    • Int J Gynecol Cancer. 2020 Oct 20:ijgc-2020-001927. doi: 10.1136/ijgc-2020-001927. Epub ahead of print.

    • ASO Author Reflections: Contralateral Prophylactic Mastectomy in Breast Cancer Patients with CHEK2 Gene Mutations.
    • Nizic-Kos T, Besic N.
    • Ann Surg Oncol. 2020 Oct 18. doi: 10.1245/s10434-020-09196-w. Epub ahead of print.
    • Commentary

    • Repurposing denosumab in breast cancer beyond prevention of skeletal related events: could nonclinical data be translated into clinical practice?
    • Deligiorgi MV, Panayiotidis MI, Trafalis DT.
    • Expert Rev Clin Pharmacol. 2020 Oct 17. doi: 10.1080/17512433.2020.1839416. Epub ahead of print.
    • Review

    • Comparison of interval breast cancers with 2D digital mammography versus 3D digital breast tomosynthesis in a large community-based practice.
    • Winter AM, Kazmi S, Hardy AK, Bennett DL.
    • Breast J. 2020 Oct 16. doi: 10.1111/tbj.14047. Epub ahead of print.

    • Genetic and clinical landscape of breast cancers with germline BRCA1/2 variants.
    • Inagaki-Kawata Y, Yoshida K, Kawaguchi-Sakita N, Kawashima M, Nishimura T, Senda N, Shiozawa Y, Takeuchi Y, Inoue Y, Sato-Otsubo A, Fujii Y, Nannya Y, Suzuki E, Takada M, Tanaka H, Shiraishi Y, Chiba K, Kataoka Y, Torii M, Yoshibayashi H, Yamagami K, Okamura R, Moriguchi Y, Kato H, Tsuyuki S, Yamauchi A, Suwa H, Inamoto T, Miyano S, Ogawa S, Toi M.
    • Commun Biol. 2020 Oct 16;3(1):578. doi: 10.1038/s42003-020-01301-9.

    • Clinical characteristics and prognostic implications of BRCA-associated tumors in males: a pan-tumor survey.
    • Sun P, Li Y, Chao X, Li J, Luo R, Li M, He J.
    • BMC Cancer. 2020 Oct 14;20(1):994. doi: 10.1186/s12885-020-07481-1.

    • The abundance of the long intergenic non-coding RNA 01087 differentiates between luminal and triple-negative breast cancers and predicts patient outcome.
    • De Palma FDE, Monaco VD, Pol JG, Kremer M, D'Argenio V, Stoll G, Montanaro D, Uszczynska-Ratajczak B, Klein CC, Vlasova A, Botti G, D'Aiuto M, Baldi A, Guigó R, Kroemer G, Maiuri MC, Salvatore F.
    • Pharmacol Res. 2020 Oct 14:105249. doi: 10.1016/j.phrs.2020.105249. Epub ahead of print.

    • Identification of Germline Mutations in Melanoma Patients with Early Onset, Double Primary Tumors, or Family Cancer History by NGS Analysis of 217 Genes.
    • Stolarova L, Jelinkova S, Storchova R, Machackova E, Zemankova P, Vocka M, Kodet O, Kral J, Cerna M, Volkova Z, Janatova M, Soukupova J, Stranecky V, Dundr P, Foretova L, Macurek L, Kleiblova P, Kleibl Z.
    • Biomedicines. 2020 Oct 9;8(10):E404. doi: 10.3390/biomedicines8100404.

    • Newly diagnosed ovarian cancer: Which first-line treatment?
    • Lorusso D, Ceni V, Daniele G, Salutari V, Pietragalla A, Muratore M, Nero C, Ciccarone F, Scambia G.
    • Cancer Treat Rev. 2020 Oct 9;91:102111. doi: 10.1016/j.ctrv.2020.102111. Epub ahead of print.
    • Review

    • The DNA damaging revolution.
    • Cetin B, Wabl CA, Gumusay O.
    • Crit Rev Oncol Hematol. 2020 Oct 3;156:103117. doi: 10.1016/j.critrevonc.2020.103117. Epub ahead of print.
    • Review

    • Genomic Analysis Reveals Novel Specific Metastatic Mutations in Chinese Clear Cell Renal Cell Carcinoma.
    • Meng H, Jiang X, Cui J, Yin G, Shi B, Liu Q, Xuan H, Wang Y.
    • Biomed Res Int. 2020 Sep 30;2020:2495157. doi: 10.1155/2020/2495157.

    • Clinical Outcome-Related Mutational Signatures Identified by Integrative Genomic Analysis in Nasopharyngeal Carcinoma.
    • Dai W, Chung DL, Chow LK, Yu VZ, Lei LC, Leong MM, Chan CKC, Ko JMY, Lung ML.
    • Clin Cancer Res. 2020 Sep 28:clincanres.2854.2020. doi: 10.1158/1078-0432.CCR-20-2854. Epub ahead of print.

    • Olaparib treatment in older patients with ovarian cancer: need for 'real-world' data beyond clinical trials.
    • Liposits G, Wulff CN, Otland A, Fokdal LU.
    • Ecancermedicalscience. 2020 Sep 15;14:1104. doi: 10.3332/ecancer.2020.1104.

    • Significance of E-cadherin Gene Mutations in Patients With Hereditary Diffuse Gastric Cancer Syndrome: A Systematic Review.
    • Goud HK, Mehkari Z, Mohammed L, Javed M, Althwanay A, Ahsan F, Oliveri F, Rutkofsky IH.
    • Cureus. 2020 Sep 12;12(9):e10406. doi: 10.7759/cureus.10406.

    • Molecular Biomarkers for Early Detection and Prevention of Ovarian Cancer-A Gateway for Good Prognosis: A Narrative Review.
    • Yadav G, Vashisht M, Yadav V, Shyam R.
    • Int J Prev Med. 2020 Sep 3;11:135. doi: 10.4103/ijpvm.IJPVM_75_19.

    • LitAlert ~~ GeneLit.com

    • Comparison of Poly (ADP-ribose) Polymerase Inhibitors (PARPis) as Maintenance Therapy for Platinum-Sensitive Ovarian Cancer: Systematic Review and Network Meta-Analysis.
    • Stemmer A, Shafran I, Stemmer SM, Tsoref D.
    • Cancers (Basel). 2020 Oct 18;12(10):E3026. doi: 10.3390/cancers12103026.

    • Isoflavone intake on the risk of overall breast cancer and molecular subtypes in women at high risk for hereditary breast cancer.
    • Sim EJ, Ko KP, Ahn C, Park SM, Surh YJ, An S, Kim SW, Lee MH, Lee JW, Lee JE, Kim KS, Yom CK, Kim HA, Park SK.
    • Breast Cancer Res Treat. 2020 Oct 17. doi: 10.1007/s10549-020-05875-0. Epub ahead of print.